This therapy resulted in the transformation of a “cold” tumor to an “inflamed” tumor and was demonstrated to be safe and effective in patients with heavily pretreated advanced TNBC, even in those negative for PD-L1, or in those who have progressed after several lines of treatment, including ICIs [151]. The gene discussed is CD274; the disease is neoplasm.